Target intelligence / Profile preview

Striatal neural circuit (None)

Target
None
Molecular classification
Other, Neural circuit
01

Overview

Striatal neural circuits" consist of complex networks of neurons within the striatum, integrating signals from the cortex, thalamus, and midbrain to regulate motor control, reward, learning, and various cognitive processes[1][6][13][16]. The principal cellular components include medium spiny neurons (MSNs)—which express dopaminergic receptors and segregate into direct and indirect pathways—and interneurons (cholinergic, GABAergic), each with distinct inputs and functional roles[3][6][9]. Striatal circuits serve as the entry point to the basal ganglia, a major system orchestrating voluntary movement and reinforcement learning[1][7][16]. These circuits are implicated in several neurological and psychiatric disorders, underpinning both normal and pathological behaviors, and are increasingly considered in neuromodulation therapies, though they are not themselves individual molecular drug targets[5][11][12][13][17].

Other names
Striatal circuitscorticostriatal circuitscortico-striatal-thalamic loopsbasal ganglia-striatal pathways
02

Mechanism of action

For drugs: Modulation of dopamine receptor activity (antagonism/agonism), GABAergic modulation, glutamatergic transmission. For devices: Modulation of circuit activity via electrical stimulation.

03

Biological functions

Motor controlReward processingCognitive functions (decision-making, evaluation, behavioral flexibility)Learning/memoryHabit formation
04

Disease associations

Neurodegenerative disease (e.g., Parkinson’s disease, Huntington’s disease)Substance use disorder/addictionPsychiatric disorders (e.g., obsessive-compulsive disorder, depression)Movement disorders
05

Safety considerations

Circuit-targeting therapies can affect motor function, cognition, and reward, potentially causing dyskinesia, neuropsychiatric symptoms, or addictionOff-target effects with device-based therapies (e.g., DBS)
06

Interacting drugs

dopaminergic agents (levodopa, dopamine agonists, antagonists)

4 more in the full profile.

07

Biomarkers

Imaging signatures (fMRI, PET scan dopamine receptor occupancy)Neurophysiological patterns (EEG, local striatal field potentials in DBS)

Beyond the preview

Go deeper on Striatal neural circuit (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Striatal neural circuit (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call